Adding GLP-1 Drugs Helps Psychiatric Patients Stay on Their Antipsychotic Medications | Research

The takeaway

Non-diabetic patients who added a GLP-1 receptor agonist to their antipsychotic regimen showed significantly better medication adherence, with 9-20% higher coverage rates and 27-41 more days of persistent use.

+41 days persistence
Medicaid patients on GLP-1 + antipsychotic stayed on their psychiatric medication 41 days longer than those on antipsychotic alone

What the researchers found

Adjuvant GLP-1RA improved antipsychotic adherence with 8.91% higher PDC (commercial) and 19.80% higher PDC (Medicaid), and 27.12 and 41.21 additional days of persistence, respectively.

Why it matters

Poor antipsychotic adherence is a major driver of psychiatric relapse and hospitalization. If GLP-1 drugs can keep patients on their medications by managing weight gain, this could significantly improve psychiatric outcomes and reduce healthcare costs.

How the study worked

Retrospective cohort study using MarketScan Commercial and Medicaid claims (2019-2023) with prescription-time-distribution matching and propensity score matching across 2,153 commercial and 787 Medicaid patients.

What this study cannot tell us

Observational retrospective design. Patients who add GLP-1 drugs may be more health-engaged overall. Cannot establish causation. Limited to 6-month primary analysis window, though 365-day sensitivity analysis showed similar results.

How to read the evidence

Retrospective claims analysis with two matching methods to address bias. Consistent results across subgroups and sensitivity analyses, but observational design.

When this study was published

Published in 2025 using 2019-2023 data, reflecting current real-world prescribing patterns.

The bigger picture

This study reveals an unexpected benefit of GLP-1 peptide drugs: improving adherence to other medications by managing their metabolic side effects. This cross-therapeutic benefit could reshape how psychiatrists approach treatment-resistant non-adherence.

Questions still open

Would prospective trials confirm that GLP-1 drugs improve psychiatric outcomes through better antipsychotic adherence?
Which GLP-1 agent is most effective at improving antipsychotic adherence?
Could insurance coverage of GLP-1 drugs for antipsychotic patients be cost-effective by preventing psychiatric hospitalizations?

Common questions

Why do people stop taking antipsychotic medications?

Weight gain is one of the most common reasons. Many antipsychotics cause significant weight increase, leading to frustration, health concerns, and ultimately medication discontinuation — which can trigger psychiatric relapse.

How do GLP-1 drugs help people stay on their antipsychotic?

By counteracting the weight gain caused by antipsychotics, GLP-1 drugs remove one of the main reasons patients stop their psychiatric medication. In this study, patients who added a GLP-1 drug stayed on their antipsychotic significantly longer.

Read the original research

Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults.

Journal of clinical psychopharmacology

View on PubMed ↗Publisher’s paper ↗

Citation

Daggolu, Jerusha; Okonkwo, Michael; Chen, Hua. (2026). Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults.. Journal of clinical psychopharmacology. https://doi.org/10.1097/JCP.0000000000002145